Key Client Fiduciary Advisors’s Cytosorbents Corp CTSO Stock Holding History

Key Client Fiduciary Advisors’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.3K	Hold	78,457	–	–	0.01%	229
2026 Q1	$44.4K	Hold	78,457	–	–	0.02%	211
2025 Q4	$50.1K	Hold	78,457	–	–	0.02%	211
2025 Q3	$73.3K	Hold	78,457	–	–	0.02%	220
2025 Q2	$100K	Hold	78,457	–	–	0.04%	202
2025 Q1	$78.5K	Buy	78,457 +43,900	+127%	+$46.3K	0.04%	188
2024 Q4	$31.4K	Hold	34,557	–	–	0.01%	193
2024 Q3	$51.8K	Hold	34,557	–	–	0.02%	198
2024 Q2	$24.3K	Hold	34,557	–	–	0.01%	189
2024 Q1	$32.8K	Buy	34,557 +22,557	+188%	+$22K	0.02%	182
2023 Q4	$13.3K	Sell	12,000 -1,000	-8%	-$1.49K	0.01%	171
2023 Q3	$24.4K	Buy	13,000 +1,000	+8%	+$2.87K	0.02%	168
2023 Q2	$43.1K	Hold	12,000	–	–	0.03%	174
2023 Q1	$40.4K	Hold	12,000	–	–	0.03%	164
2022 Q4	$18.6K	Hold	12,000	–	–	0.01%	158
2022 Q3	$16K	Hold	12,000	–	–	0.01%	109
2022 Q2	$26K	Buy	+12,000	New	+$27.6K	0.03%	111

Other funds holding CTSO

SAM

Seelaus Asset Management Chatham, New Jersey $142M AUM 48.54% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Key Client Fiduciary Advisors's CTSO Position: Q2 2026 in Review

Key Client Fiduciary Advisors held its Cytosorbents Corp (CTSO) position steady in Q2 2026 at 78,457 shares worth $29.3K. The position accounts for 0.01% of the portfolio, ranked #229.

Key Client Fiduciary Advisors first reported a position in CTSO in Q2 2022 and has held it in 17 quarters since. The position peaked at $100K in Q2 2025. 4 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.

Key Client Fiduciary Advisors held 78,457 shares of Cytosorbents Corp worth $29.3K as of Q2 2026.
Key Client Fiduciary Advisors left its Cytosorbents Corp share count unchanged in Q2 2026.
Cytosorbents Corp made up 0.01% of Key Client Fiduciary Advisors's portfolio in Q2 2026, its #229 holding.
Key Client Fiduciary Advisors first reported a position in Cytosorbents Corp in Q2 2022 and has held it in 17 quarters since.
Key Client Fiduciary Advisors's Cytosorbents Corp position peaked at $100K in Q2 2025.
4 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.

Based on Key Client Fiduciary Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.